Wang Huan, Zhang Yu, Yang Ziqi, Jiang Yong, Wu Lixue, Wang Rui, Zhang Zhang
Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Pathology, Langzhong People's Hospital, Langzhong, Sichuan, China.
Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Pathol Res Pract. 2023 Oct;250:154787. doi: 10.1016/j.prp.2023.154787. Epub 2023 Aug 28.
Breast Cancer (BC) is the most common malignant tumor for women in the world. 90% of BC-associated deaths are attributed to distant metastasis (DM). Therefore, there is an urgent need for a novel molecular target for the treatment of distant metastatic breast cancer (DMBC). Syndecan-1 (SDC-1) is a cell surface heparan sulfate proteoglycan (HSPG). This study aims to study the expression patterns of SDC-1 in invasive breast carcinoma (IBC) with DM and to analyze its relationship with different clinicopathologic features, stromal tumor infiltrating lymphocytes (sTILs) status and the clinical outcomes.
A total of 50 DM breast cancer and 100 non-distant metastasis (non-DM) breast cancer patients in West China Hospital, Sichuan University from January 1, 2011 to December 31, 2011 were collected. Immunohistochemical (IHC) method was used to detect the expression of SDC-1, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), and Ki-67 in 150 specimens of patients with IBC. STILs were used to evaluate immune cells in the stromal tissue within the tumor. Various clinicopathologic characteristics were retrospectively analyzed, and follow-up information were collected for prognosis analyses. The expression pattern difference of SDC-1 in the DM group and the non-DM group and its correlation with clinicopathologic characteristics of IBC were analyzed.
Compared with the non-DM group, SDC-1 had higher cytoplasmic (90.0%) and stromal diffuse (70.0%) expressions and lower stromal peritumoral (18.0%) expression in the DM group. SDC-1 cytoplasmic expression was significantly associated with HER2-positive and high Ki-67 index in DM group, and with high histological grade and lymph node (LN) metastasis in non-DM group (P < 0.05). Compared with the non-DM group, the membranous expression of SDC-1 in the DM group was related to higher histological grade and T stage, higher frequency of LN involvement. Meanwhile, the expression pattern of SDC-1 in tumor stroma was associated with sTILs status (P < 0.05). The different combinations of SDC-1 staining patterns were correlated with clinicopathological features, biomarkers and sTILs status between DM group and non-DM group.There was no significant difference in overall survival between DMBC with different expression patterns of SDC-1.
The cytoplasmic and stromal expressions of SDC-1 in the primary lesion of IBC are closely associated with DM, and the stromal expression of SDC-1 is correlated with tumor immune microenvironment. SDC-1 is expected to be a potential new marker for predicting the risk of DM in IBC.
乳腺癌（BC）是全球女性中最常见的恶性肿瘤。90%的乳腺癌相关死亡归因于远处转移（DM）。因此，迫切需要一种用于治疗远处转移性乳腺癌（DMBC）的新型分子靶点。Syndecan-1（SDC-1）是一种细胞表面硫酸乙酰肝素蛋白聚糖（HSPG）。本研究旨在探讨SDC-1在伴有DM的浸润性乳腺癌（IBC）中的表达模式，并分析其与不同临床病理特征、基质肿瘤浸润淋巴细胞（sTILs）状态及临床结局的关系。
收集2011年1月1日至2011年12月31日在四川大学华西医院就诊的50例DM乳腺癌患者和100例非远处转移（非DM）乳腺癌患者。采用免疫组织化学（IHC）方法检测150例IBC患者标本中SDC-1、雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER2）和Ki-67的表达。用sTILs评估肿瘤内基质组织中的免疫细胞。回顾性分析各种临床病理特征，并收集随访信息进行预后分析。分析DM组和非DM组中SDC-1的表达模式差异及其与IBC临床病理特征的相关性。
与非DM组相比，DM组中SDC-1的细胞质表达较高（90.0%）、基质弥漫性表达较高（70.0%），而基质肿瘤周围表达较低（18.0%）。DM组中SDC-1的细胞质表达与HER2阳性和高Ki-67指数显著相关，在非DM组中与高组织学分级和淋巴结（LN）转移相关（P<0.05）。与非DM组相比，DM组中SDC-1的膜性表达与较高的组织学分级和T分期、较高的LN受累频率相关。同时，SDC-1在肿瘤基质中的表达模式与sTILs状态相关（P<0.05）。DM组和非DM组中SDC-1染色模式的不同组合与临床病理特征、生物标志物和sTILs状态相关。SDC-1表达模式不同的DMBC患者总生存期无显著差异。
IBC原发灶中SDC-1的细胞质和基质表达与DM密切相关，SDC-1的基质表达与肿瘤免疫微环境相关。SDC-1有望成为预测IBC中DM风险的潜在新标志物。
